Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Ataturk University | Turkey 

Prof. Dr. Mine Gülaboğlu is a distinguished scholar in Biochemistry, Pharmacology, and Basic Pharmaceutical Sciences, currently serving as the Head of the Department of Basic Pharmaceutical Sciences at Atatürk University, Faculty of Pharmacy. She completed her Ph.D. in Medical Biochemistry in 2004, following her postgraduate specialization (1990–1993) and undergraduate training in Chemistry (1982–1986), all at Atatürk University.With extensive academic and administrative service, she has held key roles such as Faculty Board Member, Departmental Academic Incentive Evaluation Chair, Performance Evaluation Committee Member, Criteria Committee Member, and Education Committee Member. Her commitment to academic excellence is further demonstrated through numerous jury memberships for professorship, associate professorship, postgraduate examinations, doctoral thesis monitoring, and scientific evaluations.Prof. Dr. Gülaboğlu’s research focuses on health sciences, particularly biochemistry, pharmacology, therapeutics, and pharmaceutical sciences. She has authored impactful research articles in high-ranking journals such as Scientific Reports, Biomedicines, Experimental Eye Research, European Review for Medical and Pharmacological Sciences, and others. Her scientific contributions include investigations into oxidative stress, drug-induced toxicity, protective biochemical agents, nanoformulations, and molecular mechanisms underlying disease pathology.Over her career, she has completed numerous certifications, trainings, and specialized courses in molecular techniques, pharmacology, chemometrics, laboratory quality systems, education management, energy efficiency, environmental sustainability, and occupational safety. She is also proficient in English at an intermediate level.A dedicated educator, Prof. Dr. Gülaboğlu teaches a wide range of courses across undergraduate, postgraduate, and doctoral levels, including Biochemistry, Protein Separation Techniques, Vitamins and Coenzymes, Metabolism, Research Methods, and Project Courses.Prof. Dr. Mine Gülaboğlu continues to contribute profoundly to scientific research, education, and academic leadership in Türkiye, shaping future generations of pharmaceutical and biomedical scientists.

Profile: Google Scholar

Featured Publications

Altuner, D., Gulaboglu, M., Yapca, O. E., & Cetin, N. (2013). The effect of mirtazapine on cisplatin-induced oxidative damage and infertility in rat ovaries. The Scientific World Journal, 2013(1), 327240.

Bilici, M., Ozturk, C., Dursun, H., Albayrak, F., Saglam, M. B., Uyanik, A., … (2009). Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters. Digestive Diseases and Sciences, 54(9), 1868–1875.

Gulaboglu, M., Borekci, B., & Delibas, I. (2010). Urine iodine levels in preeclamptic and normal pregnant women. Biological Trace Element Research, 136(3), 249–257.

Gulaboglu, M., Borekci, B., & Halici, Z. (2007). Placental tissue iodine level and blood magnesium concentration in pre-eclamptic and normal pregnancy. International Journal of Gynecology & Obstetrics, 98(2), 100–104.

Coskun, R., Turan, M. I., Turan, I. S., & Gulapoglu, M. (2014). The protective effect of thiamine pyrophosphate, but not thiamine, against cardiotoxicity induced with cisplatin in rats. Drug and Chemical Toxicology, 37(3), 290–294.

Gulaboglu, M., Yildiz, L., Celebi, F., Gul, M., & Peker, K. (2005). Comparison of iodine contents in gastric cancer and surrounding normal tissues. Clinical Chemistry and Laboratory Medicine, 43(6), 581–584.

Özer, A. K., Gülaboğlu, M., & Bayrakçeken, S. (2000). Physical structure and chemical and mineralogical composition of the Mazıdağı (Turkey) phosphate rock. Industrial & Engineering Chemistry Research, 39(3), 679–683.

Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U. P., Yang, X., Liu, Z., Altwegg, K. A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H. B., Ford, A., Dick, E. J., Jr., Hill, R. H., Jr., & VandeBerg, J. L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H. B., Kesavaram, N., Das, B., Garfield, R., Shi, S. Q., … Edwards, D. P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., … Nair, H. B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N. M., Nair, H. B., Liu, Y. G., Kirma, N. B., Binkley, P. A., Kumar, S., … Tekmal, R. R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication Profile 

Orcid

Education 

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

Experience 

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and Honors 

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research Focus 

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

E Marimuthu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. E. Marimuthu | Drug Discovery and Development | Best Researcher Award

Professor at Arunachal University of Studies | Ayya Nadar Janaki Ammal College | Madurai Kamaraj University | India

Dr. E. Marimuthu is a dedicated researcher and academician specializing in plant biotechnology, microbiology, and molecular biology. With over 15 years of experience in research and education, he has made significant contributions through patents, microbial sequencing, and ethnobotanical surveys. His work focuses on endangered species conservation, natural IAA production, and nanomedicine applications for cancer. Dr. Marimuthu currently serves as a Professor at Arunachal University of Studies. His multidisciplinary efforts bridge traditional knowledge with modern scientific innovations, making him a standout figure in applied life sciences and pharmaceutical biotechnology.

Publication Profile 

Scopus 

Education

Dr. Marimuthu earned his Ph.D. from Madurai Kamaraj University in 2017, focusing on the in vitro conservation of endangered tree species in the Southern Western Ghats . He completed his M.Phil. and M.Sc. from Ayya Nadar Janaki Ammal College, conducting ethnomedicinal surveys and plant growth hormone studies. His academic foundation began with a B.Sc. in Botany. Each academic milestone has been rooted in biodiversity conservation and plant-microbe interactions, establishing a strong base for his later patents and microbial gene discoveries .

Experience

Dr. Marimuthu has held various academic and research roles: Professor and Associate Professor at Arunachal University of Studies (2023–present), Assistant Professor at Sri Vidya Mandir and Vivekanandha Colleges, and Associate Scientist at Aakash Green Research Pvt. Ltd. Earlier, he served as a JRF at TBGRI, Kerala  and Technical Assistant at Kalasalingam University. His experience spans plant tissue culture, cell line work, and microbial molecular studies. With deep involvement in both lab and field research, he has nurtured innovations from concept to patent, while also mentoring students and contributing to curriculum development.

Awards 

Dr. E. Marimuthu is a prolific innovator with 8 Indian patents and 2 Canadian patents, showcasing breakthroughs in nanomedicine, cancer immunotherapy, and plant-based biotechnology . His bacterial gene sequences are submitted to NCBI, emphasizing novel microbial discoveries from unique ecological niches. Recognized nationally and internationally for his translational research, he has pioneered techniques that merge traditional plant knowledge with high-end scientific platforms. Though specific named awards are not listed, his patent record and academic promotions signify a distinguished and respected trajectory in bioscience innovation and interdisciplinary research.

Research Focus 

Dr. Marimuthu’s research emphasizes plant tissue culture, natural growth hormone production, ethnomedicinal conservation, and nanotechnology-enhanced drug delivery . He explores molecular markers for documenting genetic diversity and has successfully isolated bacterial strains producing Indole-3-acetic acid (IAA) to promote plant growth . He integrates ethnobotanical knowledge with biotechnological advancements to develop eco-friendly, scalable solutions for agriculture and medicine. His cutting-edge work in cancer-targeting mesenchymal stem cell therapy, as well as nano-immunotherapy, reflects a visionary outlook on the future of personalized medicine and sustainable pharmacology.

Publication Top Notes

Title: Chemical profiling and in silico molecular docking studies of phytochemicals from Hydnocarpus macrocarpa Warb: A GC–MS, FTIR, and physico-chemical analysis
Journal: Journal of Molecular Structure
Year: 2025

Conclusion

Dr. E. Marimuthu is an outstanding candidate for the Best Researcher Award, showcasing a rare combination of field knowledge, lab precision, patent-oriented innovation, and a commitment to both fundamental and applied science. His work contributes significantly to biotechnology, pharmacology, environmental microbiology, and regenerative agriculture.

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Prof. Dr. Reda Abdel-Hameed, University of Hail, Egypt

Prof. Dr. Reda Abdel-Hameed is a distinguished chemist specializing in applied physical chemistry. He earned his B.Sc. (1998), M.Sc. (2003), and Ph.D. (2006) from Al-Azhar University, Cairo. With over two decades in academia, he has served as a professor at Al-Azhar University and an associate professor at the University of Hail, Saudi Arabia. His prolific research includes 134 published papers on nanotechnology, drug design, and environmental chemistry. A leader in scientific innovation, he continues to shape the future of chemistry through groundbreaking studies and mentorship.

Publication Profile

Google Scholar

Education

Prof. Dr. Reda Abdel-Hameed 🎓 is a distinguished chemist with a strong academic background. He earned his B.Sc. in Chemistry in 1998 with an Excellent with Honor degree 🏅, followed by an M.Sc. in Applied Organic Chemistry in 2003 and a Ph.D. in Applied Physical Chemistry in 2006. His academic career began as a Demonstrator at Al-Azhar University (1998-2003) and progressed to Lecturer (2003-2006), Assistant Professor (2006-2012), and Associate Professor (2012-2017). He also served at Hail University, KSA (2009-2012). Since 2017, he has been a Full Professor at Al-Azhar University, contributing significantly to the field of chemistry 🔬.

Experience 

Prof. Dr. Reda Abdel-Hameed 📚 has an extensive teaching portfolio in chemistry across Al-Azhar University and Hail University. At Al-Azhar, he has taught courses in Physical Chemistry, Electrochemistry, Polymer Science, Industrial Chemistry, and more 🔬. At Hail University, he covered Applied Physical Chemistry, Quantum Chemistry, Medical Chemistry, and Petroleum Chemistry ⛽. Additionally, he played a key role in developing course specifications and descriptions. His contributions extend to authorship, with books like Introduction to Organic Chemistry, Applied Electrochemistry, and Nanocomposites as Corrosion Inhibitors 📖. His dedication to chemistry education continues to inspire students worldwide 🌍.

Awards

Prof. Dr. Reda Abdel-Hameed 🌍 is a globally recognized scientist, ranked among the world’s top 2% by Stanford University and Elsevier from 2019 to 2023 📊. His excellence in academia has earned him numerous accolades, including the Ideal Student Prize (1996-1997) 🏆, the Faculty of Science Award for Academic Affairs (2012), and the Excellence in Teaching Award (2017) 🎓. He was also honored for integrating technology into higher education (2010) and recognized as the Best Coordinator for Student Activities at Hail University (2016). A proud member of the Royal Society of Chemistry (RSC) 🔬, he continues to make remarkable contributions.

Research Focus

Prof. Dr. Reda S. Abdel-Hameed specializes in corrosion science and electrochemical applications ⚡🔬. His research focuses on developing corrosion inhibitors 🛡️ for metals, particularly in acidic and marine environments. He explores green chemistry approaches 🌱, including eco-friendly inhibitors derived from expired drugs 💊, polymers 🏗️, and heterocyclic compounds 🧪. His work advances electrochemical techniques for evaluating materials’ durability and protection in industrial applications 🏭. With significant contributions to nanotechnology-based inhibitors 🧬 and adsorption studies, his research benefits sectors like petrochemicals, metallurgy, and coatings 🏗️. His expertise in analytical electrochemistry helps mitigate corrosion-related challenges, ensuring sustainability and efficiency.

Publication Top Notes

Analytical application using modern electrochemical techniques

Ranitidine drugs as non-toxic corrosion inhibitors for mild steel in hydrochloric acid medium

Preparation of green cardanol-based epoxy and hardener as primer coatings for petroleum and gas steel in marine environment

Aminolysis of polyethylene terephthalate waste as corrosion inhibitor for carbon steel in HCl corrosive medium

Effect of expired drugs as corrosion inhibitors for carbon steel in 1M HCL solution

2-(2, 6-dichloranilino) phenyl acetic acid drugs as eco-friendly corrosion inhibitors for mild steel in 1M HCl

Expired Voltaren drugs as corrosion inhibitor for aluminium in hydrochloric acid

Nano-composite as corrosion inhibitors for steel alloys in different corrosive media

Corrosion inhibition and adsorption properties of some heterocyclic derivatives on C-steel surface in HCl

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Prof. Maysoon Al-Haideri| Drug Discovery |Best Researcher Award

Published on by Top Pharmaceutical

Prof. Maysoon Al-Haideri|Drug Discovery|Best Researcher Award

Prof. Maysoon Al-Haideri at University oh Kurdistan Hewlêr,Iraq

PROFILE  

scopus 

 

Early Academic Pursuits 🎓

Dr. Al-Haideri began her educational journey at Baghdad University, where she completed her B.Sc. in Pharmacy in 1973. She demonstrated early promise and a strong interest in clinical analysis, leading her to pursue an Advanced Diploma in Clinical Analysis from Baghdad University between 1977 and 1979. Her academic curiosity and pursuit of excellence took her to the United States, where she attended Columbia University in the City of New York, earning a Master of Arts (M.A.) in 1983, followed by an M.Phil. in Pathology in 1985. Her dedication and passion culminated in a Ph.D. in Pathology from Columbia University in 1987, marking the beginning of an illustrious career in clinical research and academia.

Professional Endeavors 🩺

Dr. Al-Haideri’s professional career began in Iraq, where she gained practical experience and took on leadership roles in several medical institutions. She completed a traineeship in Clinical Hematology, Clinical Biochemistry, Medical Microbiology, Parasitology, and Infectious Diseases at the Ministry of Health in Baghdad from 1974 to 1975. Following this, she served as the Director of the Clinical Laboratory at Abo-Alkhaseab Hospital in Basrah (1975-1976) and Chief of the Clinical Biochemistry and Hematology Divisions at Al-Khadmia Teaching Hospital in Baghdad (1976-1981). During this time, she was also responsible for student supervision and training, highlighting her commitment to fostering the next generation of healthcare professionals.

From 1981 to 1982, Dr. Al-Haideri took on a national role as the Director of Quality Control and Standardization for all public clinical laboratories in Iraq, ensuring the consistent application of best practices in clinical analysis. Her leadership and expertise were further recognized when she undertook a traineeship in infertility at the Ministry of Health in Baghdad in 1982, signaling her growing influence in medical diagnostics and reproductive health.

In the United States, Dr. Al-Haideri continued her impressive trajectory, completing a postdoctoral fellowship at North Shore University Hospital, Manhasset, New York (1987-1988), followed by research positions at Long Island Jewish Medical Center (1988-1990) and Albert Einstein College of Medicine, Bronx, New York (1989-1991). During this time, she held the title of Instructor of Immunology, Rheumatology, and Allergy. Dr. Al-Haideri’s academic and research career reached new heights when she joined Columbia University’s College of Physicians and Surgeons, where she worked as an NIH Postdoctoral Research Trainee (1991-1994), eventually becoming an Associate Research Scientist and Assistant Professor (1994-2004).

Contributions and Research Focus 🔬

Dr. Al-Haideri’s research has primarily focused on clinical pathology, immunology, rheumatology, and allergy. Her work has been instrumental in enhancing the understanding of immunological responses in various pathological conditions. She has been actively involved in numerous research projects, often collaborating with leading medical institutions in both the U.S. and Iraq.

Her role as Director of Quality Control and Standardization in Iraq’s Ministry of Health laid the groundwork for the development of national policies aimed at ensuring the accuracy and reliability of clinical laboratory diagnostics across the country. In the U.S., her work at prestigious institutions like Columbia University and Albert Einstein College of Medicine helped advance the field of immunology, particularly in relation to autoimmune diseases.

Accolades and Recognition 🏆

Dr. Al-Haideri’s work has been widely recognized through various awards and honors. She received NIH Grant Awards from 1991 to 1994, which supported her groundbreaking research in immunology and pathology. Her academic excellence was also acknowledged at Columbia University, where she was awarded Graduate Research Assistantships.

Her commitment to medical education and healthcare development in Iraq earned her numerous accolades, including being named Employee of the Year at Hawler Medical University in Erbil, Kurdistan in 2012. Additionally, she received letters of appreciation from the Minister of Higher Education and Scientific Research in the Kurdistan region, as well as from the President of Hawler Medical University and several deans of colleges at the university for her contributions to education and healthcare.

Impact and Influence 🌍

Dr. Al-Haideri has had a profound impact on medical education and healthcare both in Iraq and abroad. As a leader in various institutions, she has played a critical role in shaping the medical education system in the Kurdistan Region of Iraq. Her tenure as Dean of the College of Health Sciences at Hawler Medical University (2014-2018) and Director of Quality Assurance (2010-2015) helped set new standards for academic excellence and institutional leadership in the region.

Her influence extends beyond academia. Dr. Al-Haideri has been an active member of numerous professional societies, including the American Society for Biochemistry and Molecular Biology and the American Heart Association, further cementing her status as a respected expert in her field. Her involvement in international organizations, such as the International Institute of Education in New York, reflects her commitment to global collaboration and knowledge exchange.

Legacy and Future Contributions 🔮

Dr. Maysoon Tahir Al-Haideri’s legacy is one of dedication to advancing medical knowledge, improving healthcare systems, and fostering academic excellence. Her work has had a lasting impact on the clinical and academic landscapes in Iraq, particularly in the Kurdistan region, where she has influenced generations of healthcare professionals through her leadership roles at Hawler Medical University and Cihan University-Erbil.

As she continues her work as the Director of the Pharmacy Program at the University of Kurdistan Hewler, Dr. Al-Haideri remains committed to mentoring students and contributing to the development of the healthcare sector in the region. Her achievements serve as an inspiration to future generations of scientists, educators, and healthcare professionals, ensuring her legacy will endure for years to come.

🎓Publication 

Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells and increases inflammatory CD8+ cells in tumor-bearing mice

  • Authors   :Al-Haideri, M.
  • Journal    :Clinics and Research in Hepatology and Gastroenterology
  • Year         :2024

Functional and financial analysis of an inclined step solar desalination using phase change nanomaterials

  • Authors   : Mahal, A., Al-Haideri, M., Alkhouri, A., Obaidullah, A.J., Duan, M.
  • Journal    :Water Science and Technology
  • Year         :2024

Tuning the optoelectronic properties of selenophene-diketopyrrolopyrrole-based non-fullerene acceptor to obtain efficient organic solar cells through end-capped modification

  • Authors   :Ijaz, R., Waqas, M., Mahal, A., … Alatawi, N.S., Aloui, Z.
  • Journal    :Journal of Molecular Graphics and Modelling,
  • Year         :2024

Rational designing of phenothiazine dioxide based hole transporting materials for efficient perovskite solar cells

  • Authors   : Hanan, M., Umair, Mahal, A., … Farooq, Z., Mahr, M.S.
  • Journal    : Solar Energy,
  • Year         :2024

Linking the increasing epidemiology of scrub typhus transmission in India and South Asia: are the varying environment and the reservoir animals the factors behind?

  • Authors   : Mohapatra, R.K., Al-Haideri, M., Mishra, S., … Mohanty, A., Sah, R.
  • Journal    :Frontiers in Tropical Diseases,
  • Year         :2024